Related references
Note: Only part of the references are listed.Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis
Laura J. Carbone et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
Chikara Komiya et al.
PLOS ONE (2016)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Pharmacological inhibition of adipocyte fatty acid binding protein alleviates both acute liver injury and non-alcoholic steatohepatitis in mice
Ruby L. C. Hoo et al.
JOURNAL OF HEPATOLOGY (2013)
Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines
Elaine Hui et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice
AM Xu et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Share Paper
